{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:59:08Z","timestamp":1761947948729,"version":"3.40.4"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T00:00:00Z","timestamp":1394064000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0090295","type":"journal-article","created":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T21:43:40Z","timestamp":1394142220000},"page":"e90295","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C"],"prefix":"10.1371","volume":"9","author":[{"given":"Anita J.","family":"Brogan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra E.","family":"Talbird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baris","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,3,6]]},"reference":[{"key":"ref1","unstructured":"World Health Organization (WHO) (2011) Hepatitis C. Available: http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/<\/ext-link>. Accessed 10 February 2012."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"GL Armstrong","year":"2006","journal-title":"Ann Int Med"},{"key":"ref3","unstructured":"Centers for Disease Control and Prevention (CDC) (2011) Hepatitis C information for health professionals: statistics and surveillance. Available: http:\/\/www.cdc.gov\/hepatitis\/HCV\/StatisticsHCV.htm<\/ext-link>. Accessed 13 February 2012."},{"volume":"138","key":"ref4","unstructured":"Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW (2010) Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138<\/volume>: : 513\u2013521, 521, e1\u2013e6."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimate of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"HH Thein","year":"2008","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3748\/wjg.14.1652","article-title":"Natural history of hepatitis-related hepatocellular carcinoma","volume":"14","author":"DYK But","year":"2008","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2105\/AJPH.90.10.1562","article-title":"Estimating future hepatitis C morbidity, mortality, and costs in the United States","volume":"90","author":"JB Wong","year":"2000","journal-title":"Am J Public Health"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.gastro.2006.06.007","article-title":"Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States","volume":"131","author":"OV Nainan","year":"2006","journal-title":"Gastroenterology"},{"volume":"11 (10 Suppl)","key":"ref9","unstructured":"McHutchison JG, Bacon BR (2005) Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 11 (10 Suppl)<\/volume>: : S286\u2013S295."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"MP Manns","year":"2001","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"MW Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2009.06.018","article-title":"Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis","volume":"51","author":"C Camm\u00e0","year":"2009","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"IM Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"S Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"ref15","unstructured":"Vertex Pharmaceuticals Incorporated (2012) INCIVEK (telaprevir) film coated tablets [prescribing information]. Cambridge, MA: Vertex Pharmaceuticals Incorporated."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon-\u03b1 is associated with improved outcome in HCV-related cirrhosis: a retrospective study","volume":"45","author":"S Bruno","year":"2007","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"BJ Veldt","year":"2007","journal-title":"Ann Int Med"},{"key":"ref18","first-page":"1131","article-title":"Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology","volume":"32","author":"T Poynard","year":"2000"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"MG Ghany","year":"2009","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"P Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"ref21","first-page":"855","article-title":"Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Int Med","volume":"127","author":"WG Bennett","year":"1997"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/lt.22072","article-title":"Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model","volume":"16","author":"S Saab","year":"2010","journal-title":"Liver Transplantation"},{"key":"ref23","first-page":"1332","article-title":"Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut","volume":"55","author":"R Grieve","year":"2006"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1600-6143.2010.03037.x","article-title":"Liver transplantation in the United States, 1999\u20132008","volume":"10 (4 pt2)","author":"PJ Thuluvath","year":"2010","journal-title":"Am J Transplant"},{"key":"ref25","unstructured":"National Cancer Institute (NCI) (2009) Fast stats: an interactive tool for access to SEER cancer statistics. Liver and intrahepatic bile duct cancer; complete prevalence. SEER November 2009 submission. Available: http:\/\/seer.cancer.gov\/faststats<\/ext-link>. Accessed 24 February 2011."},{"key":"ref26","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1572-0241.2005.40976.x","article-title":"Estimation of utilities for chronic hepatitis C from SF-36 scores","volume":"100","author":"HH Thein","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"ref27","unstructured":"Micromedex Redbook Online 2.0 (2013) Available: http:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/<\/ext-link>. Accessed 1 April 2013."},{"key":"ref28","unstructured":"Centers for Medicare and Medicaid Services (2012) Medicare\/Medicaid clinical laboratory fee schedule (CMS Lab 2012). Available: https:\/\/www.cms.gov\/ClinicalLabFeeSched\/<\/ext-link>. Accessed 19 April 2012."},{"key":"ref29","unstructured":"Centers for Medicare and Medicaid Services (2012) Medicare\/Medicaid physician fee schedule for 2012 (CMS Phys 2012). Available: https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/<\/ext-link>. Accessed 19 April 2012."},{"key":"ref30","unstructured":"Darbinian JA, Velez FF, Quesenberry CP, Ray GT, Deniz B, et al<\/etal>.. (2010) The effect of hepatitis C treatment response on medical costs: a 5-year longitudinal analysis in a managed care setting. Poster presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA. October 30-November 3, 2010. Available: http:\/\/www.natap.org\/2010\/AASLD\/AASLD_60.htm<\/ext-link>. Accessed 3 August 2011."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.18553\/jmcp.2011.17.7.531","article-title":"All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective","volume":"17","author":"C McAdam-Marx","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"ref32","unstructured":"US Department of Veterans Affairs (USDVA) (2010) National Hepatitis C Program Office. Clinical manual: interferon and ribavirin treatment side effects. Available: http:\/\/www.hepatitis.va.gov\/provider\/reviews\/treatment-side-effects.asp<\/ext-link>. Accessed 4 April 2013."},{"key":"ref33","unstructured":"Wright K, Becker S (2003) Side effect management of hepatitis C treatment. HCV Advocate [online] 6. Available: http:\/\/www.hcvadvocate.org\/news\/NewsUpdates_pdf\/2.4.1_HCV_Advocate_2003\/advocate0303.pdf<\/ext-link>. Accessed 27 December 2010."},{"key":"ref34","first-page":"1303","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology","volume":"122","author":"T Poynard","year":"2002"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hep.20073","article-title":"Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data","volume":"39","author":"C Camm\u00e0","year":"2004","journal-title":"Hepatology"},{"key":"ref36","first-page":"485A","article-title":"Follow-up on SVR durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis of the EXTEND study","volume":"54","author":"KE Sherman","year":"2011","journal-title":"Hepatology"},{"key":"ref37","unstructured":"Mini\u00f1o AM, Murphy SL, Xu J, Kochanek KD, Division of Vital Statistics (2011) Deaths: final data for 2008. Table 3. Number of deaths and death rates, by age, race, and sex: United States, 2008. National Vital Statistics Reports 59). Available: http:\/\/www.cdc.gov\/nchs<\/ext-link>. Accessed 19 April 2012."},{"key":"ref38","unstructured":"US Bureau of Labor Statistics (BLS) (2012) Consumer Price Index\u2014all urban consumers; medical care. Series ID: CUUR0000SAM (not seasonally adjusted) [value for 2012 selected from June 2012]. Available: http:\/\/data.bls.gov\/cgi-bin\/surveymost?cu<\/ext-link>. Accessed 14 September 2012."},{"key":"ref39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1016\/S0168-8278(12)61181-7","article-title":"Health-related quality-of-life among genotype 1 treatment-na\u00efve chronic hepatitis C patients receiving telaprevir combination treatment: post-hoc analyses of data from the advance trial","volume":"56","author":"Z Younossi","year":"2012","journal-title":"J Hepatol"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. New York: Oxford University Press.","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1365-2893.2009.01136.x","article-title":"Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort","volume":"16","author":"HH Thein","year":"2009","journal-title":"J Viral Hepat"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MLR.0b013e31815c31a7","article-title":"What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule","volume":"46","author":"RS Braithwaite","year":"2008","journal-title":"Med Care"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.290.2.228","article-title":"Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population","volume":"290","author":"JA Salomon","year":"2003","journal-title":"JAMA"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"e26783","DOI":"10.1371\/journal.pone.0026783","article-title":"Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients","volume":"6","author":"S Liu","year":"2011","journal-title":"PLoS One"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MCG.0b013e3181e12c09","article-title":"Direct economic burden of chronic hepatitis C virus in a United States managed care population","volume":"45","author":"KL Davis","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices\u2014Modeling Studies","volume":"6","author":"MC Weinstein","year":"2003","journal-title":"Value Health"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/j.1572-0241.2004.30286.x","article-title":"Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C","volume":"99","author":"SD Sullivan","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1111\/j.1572-0241.2003.t01-1-08735.x","article-title":"Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C","volume":"98","author":"JB Wong","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","article-title":"New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis","volume":"156","author":"S Liu","year":"2012","journal-title":"Ann Int Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jcv.2006.04.008","article-title":"Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection","volume":"36","author":"J Hornberger","year":"2006","journal-title":"J Clin Virol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2165\/00019053-200826110-00006","article-title":"A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B","volume":"26","author":"DE Spackman","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/11587490-000000000-00000","article-title":"US cost effectiveness of darunavir\/ritonavir 600\/100 mg bid in treatment experienced, HIV infected adults with evidence of protease inhibitor resistance included in the TITAN trial","volume":"28","author":"A Brogan","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/01.qai.0000160406.08924.a2","article-title":"Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease","volume":"39","author":"PE Sax","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jval.2011.06.006","article-title":"Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C","volume":"14","author":"R Townsend","year":"2011","journal-title":"Value Health"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"G Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Brogan AJ, Talbird SE, Thompson JR, Miller JD, George S, et al<\/etal>.. (2012) Cost-effectiveness of first-line versus second-line telaprevir combination treatment in the management of chronic hepatitis C virus infection for treatment-na\u00efve patients with IL28B genotype CC. Podium presentation at Digestive Disease Week; May 19\u201322. San Diego, CA.","DOI":"10.1016\/S0016-5085(12)60648-9"},{"key":"ref58","first-page":"173","article-title":"Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection","volume":"5","author":"E Druyts","year":"2013","journal-title":"Clin Epidemiol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0090295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:30:49Z","timestamp":1746145849000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0090295"}},"subtitle":[],"editor":[{"given":"Yazdan","family":"Yazdanpanah","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,6]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0090295","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2014,3,6]]}}}